Literature DB >> 6336602

Identification of a human pancreatic duct tissue-specific antigen.

D V Gold, P Hollingsworth, T Kremer, D Nelson.   

Abstract

Antiserum raised against a pancreatic duct mucin was absorbed with type AB red blood cells and used in the indirect immuno-glucose oxidase procedure to examine tissue specificity. All mucin-producing organs were stained by this antiserum. Absorption of the antiserum with mucinous ovarian cystadenocarcinoma fluid eliminated generalized mucin staining, and only pancreatic ducts and colonic goblet cells were positive. Further absorption with purified colonic mucin revealed a pancreatic duct tissue-specific determinant(s). This tissue-specific determinant(s) was detected in the RIP-1 and RIP-2 human pancreatic adenocarcinomas carried as xenografts in athymic nude mice. Because the majority of pancreatic adenocarcinomas are believed to arise from ductal tissue, pancreatic duct mucin may have a useful role as a marker in detection and differential diagnosis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6336602

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Differential mucin gene expression in human pancreatic and colon cancer cells.

Authors:  S Yonezawa; J C Byrd; R Dahiya; J J Ho; J R Gum; B Griffiths; D M Swallow; Y S Kim
Journal:  Biochem J       Date:  1991-06-15       Impact factor: 3.857

2.  Comparative studies on the expression of gastrointestinal-cancer-associated antigen, PA8-15, CA19-9 and the blood-group antigens in non-malignant and malignant human pancreatic tissues.

Authors:  H Egami; K Sakamoto; R Yoshimura; M Arai; Y Takiyama; P M Pour
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

3.  Enzymic determination of acidic glycoconjugates in human pancreatic juice.

Authors:  S Yoshihara; M Sasaki; H Kawasaki; M Yokoyama; M Endo; M Konn
Journal:  Int J Pancreatol       Date:  1993-12

4.  Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin.

Authors:  David V Gold; Guy Newsome; Donglin Liu; David M Goldenberg
Journal:  Mol Cancer       Date:  2013-11-20       Impact factor: 27.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.